AMTM / RESEARCH · ↑ INDEX 2026-04-30
Silent Engineering Fund
April 30, 2026
AMTM
Amentum Holdings, Inc.
Analysis Date: 2026-04-30 Exchange: NYSE Sector: Industrials — Engineering & Defense Services
OVERWEIGHT

Amentum Holdings walks the narrow ridge between a forty-seven-billion-dollar fortress and a balance sheet that still bears the scars of its own making. Born from the 2024 union of legacy Amentum and Jacobs Critical Mission Solutions, the company now stands as one of the largest pure-play government engineering specialists on the exchange — yet it trades at barely half the multiple of cleaner peers. The contradiction is the story. On one flank: a backlog covering more than three years of revenue, a book-to-bill ratio north of one, and a nuclear renaissance that is no longer hypothetical — Rolls-Royce SMR deployments, EDF life-extension frameworks, and Dutch reactor programs are all under contract. On the other: net leverage at three-point-four times, GAAP net margins thinner than government letterhead, and a quarterly free-cash-flow print that reminded everyone what a government shutdown feels like from the inside. The market has priced in the scars and discounted the fortress. The question is whether May's earnings call confirms which side of the ridge holds firmer ground.

Sources: Amentum FY2025 10-K (Nov 25 2025), Q1 FY2026 Earnings Release (Feb 9 2026), BusinessWire, SEC EDGAR CIK 0002011286, MarketBeat consensus, Yahoo Finance price data.

Confidence: Medium-High (backlog and contract data are primary-source; TAM share assumptions are estimated).

Gaps: Specific customer-by-revenue breakdown not disclosed; Q2 FY2026 results not yet available; funded-to-total backlog conversion rate uncertain.

Portfolio Decision

Begin building a 3% position in AMTM at current levels ($25.50-$26.50), scaling to 4% upon Q2 FY2026 earnings confirmation on May 12 (Adj. EPS >= $0.50, guidance reaffirmed). Set stop-loss at $22.50. The thesis is anchored in a $47.2B backlog at 3.3x revenue coverage, a 9.5x forward P/E at 43% peer discount, and margin expansion from 7.7% to 8.1%. Key near-term catalysts are the May 12 earnings release and FY2027 NDAA markup. Exit immediately if Q2 EPS falls below $0.50 or if management pulls FY2026 guidance. Time horizon: 3-6 months.

Amentum is a post-merger government engineering and technology specialist trading at a significant discount to cleaner peers due to three perceived headwinds: (1) GAAP margin confusion from merger amortization, (2) government shutdown disruption in Q1 FY2026, and (3) high leverage from the Jacobs CMS combination. All three are improving: adjusted EBITDA margins expanded 40bps YoY, the shutdown was a transient event, and net leverage declined from 4.5x to 3.4x with a 3.0x year-end target. The $47.2B backlog with 1.1x LTM book-to-bill provides exceptional revenue visibility, while the nuclear renaissance and missile defense modernization create multi-year growth runways. The Partial Pass on the TAM-to-revenue conversion math tempers conviction from Buy to Overweight.

Quantitative Lane

Customer Concentration

U.S. Federal: ~80% (DoD 40-50%, DOE major, NASA growing). Allied International: 10-15%. Commercial: 5-10%. DoD single-department concentration is the dominant single-event risk.

Backlog & Book-to-Bill
Total Backlog$47.2BQ1 FY2026
Funded$6.9B14.6% of total
Book-to-Bill (LTM)1.10xExpanding
Book-to-Bill (Qtr)1.00xAt Parity
YoY Backlog+4%Growing
Net Bookings (Qtr)$16.3BQ1 FY2026
Channel Checks
  • ✓Book-to-Bill (LTM) > 1.0x — 1.10x — modestly above parity; pipeline expandingpass
  • −Book-to-Bill (Qtr) > 1.0x — 1.0x — flat at parity; needs Q2 confirmationmarginal
  • ✓YoY backlog growth positive — +4% — directionally favorable, modest pacepass
  • ✓Net bookings cover ≥ 1Q revenue — $16.3B Q1 bookings vs ~$3.7B quarterly revenue (4.4x cover)pass
  • ✗Funded backlog ≥ 25% of total — Only 14.6% funded; 85% subject to FY27 NDAA appropriations riskfail
  • ✓Multi-domain win flow last quarter — MDA, USAF, EDF, Rolls-Royce, Dutch KGG, DISA — defense + nuclear + intelpass
  • −Top single contract risk-concentrated — MDA SHIELD ceiling large but task-order driven; conversion risk materialmarginal
Notable Recent Wins
  • MDA SHIELD$151B ceilingIDIQ ceiling award
  • USAF RPA$995MSingle-award contract
  • EDF (France)$730MNuclear life-extension framework
  • Rolls-Royce SMR—JV / SMR program
  • Dutch KGG$207MTask order
  • DISA$120MTask order

$47.2B backlog provides ~3.3x revenue coverage. LTM book-to-bill above 1.0 confirms expansion, but only 14.6% is funded — execution risk hinges on FY27 NDAA passage and continued task-order flow under MDA SHIELD.

Catalyst Calendar
Q2 FY2026 EarningsMay 12, 2026FY2027 NDAA MarkupMay-Jun 2026FY2027 DoD POMJun 30, 2026USAF RPA RampQ3 FY2026 CATALYST TIMELINE

Catalyst nodes are color-coded by impact (red=high, amber=medium, tan=low).

DateEventImpact
May 12, 2026Q2 FY2026 Earnings — First look at shutdown recovery; guidance updateHigh
May-Jun 2026FY2027 NDAA Markup — DoD authorization levelsHigh
Jun 30, 2026FY2027 DoD POM — 5-year spending planMedium
H2 2026UK SMR Wylfa Milestones — Litmus Nuclear JVMedium
H2 2026MDA SHIELD Task Orders — $151B ceiling IDIQ task flowHigh
Q3 FY2026USAF RPA Ramp — $995M single-awardMedium
FY2026 YENet Leverage 3.0x Target — Debt reduction milestoneMedium

Research Manager

Investment Plan — Overweight

Rationale:

The bull case has structural merits that the bear case cannot fully dismantle: a $47.2B backlog providing 3.3x revenue coverage, an LTM book-to-bill of 1.1x indicating demand exceeding supply, margin expansion from 7.7% to 8.1%, and a forward P/E of 9.5x at a 43% discount to cleaner peers. The bear is correct that funded backlog ($6.9B) is a small fraction of total, that government dependency creates recurring shutdown risk, and that Q1 FCF of -$142M raises questions about the steep ramp required to meet FY2026 FCF guidance. However, the concrete catalyst alignment (Q2 earnings May 12, NDAA markup May-June) will provide definitive evidence. The kill-switch (Adj. EPS below $0.50 on May 12) provides a clear exit criterion. The partial weakness on the TAM-to-revenue conversion math justifies capping conviction at Overweight rather than Buy.

Strategic Actions:

Begin building a position at current levels ($26.23), with a target allocation of 3-5% of portfolio. Use May 12 Q2 earnings as a confirmation gate: if Adj. EPS exceeds $0.50 and management reaffirms FY2026 guidance, add to the position toward the 5% target. If Q2 Adj. EPS falls below $0.50, exit immediately. Set stop-loss at $22.00. Price target: $34.00 (~30% upside).

Trader

Transaction Proposal — Buy

Action: Buy

Reasoning: Amentum presents an asymmetric risk/reward at $26.23. The forward P/E of 9.5x prices in worst-case assumptions on shutdown disruption and margin pressure, while the $47.2B backlog, 1.1x LTM book-to-bill, and concrete near-term catalysts (May 12 earnings, NDAA markup) provide clear positive catalysts. The kill-switch at $0.50 Q2 EPS provides a defined exit. The risk is bounded by the $22 support zone (~16% downside) while upside to the $34 consensus target is ~30%.

Entry Price: $25.50-$26.50

Stop Loss: $22.00

Position Sizing: 3-5% of portfolio, built in two tranches: 2% initial, 2-3% added after May 12 Q2 earnings confirmation

FINAL TRANSACTION PROPOSAL: BUY

Investment Debate

Bull Researcher

ROUND 1: Two dated catalysts (Q2 earnings May 12, NDAA markup May-June). Nuclear TAM $50B by 2030; 5% share = $2.5-3.5B rev. MDA SHIELD 2-3% of $151B = $3-4.5B cumulative. FY2027 POM cycle and NDAA support mission areas. Industry consolidation creates demand-pull. Kill-switch: Q2 Adj EPS below $0.50 breaks thesis. Forward P/E 9.5x at 43% peer discount. $47.2B backlog = 3.3x coverage. Deleveraging from 4.5x to 3.4x, Moody's upgraded Ba3.

ROUND 2: Unfunded backlog is standard in government contracting — single-award contracts like USAF RPA and EDF have high conversion. LTM B2B 1.1x matters more than quarterly 1.0x. $16.3B Q1 bookings > 1 year revenue. FCF guidance $525-575M sufficient for debt service and deleveraging. Margins expanding 7.7% to 8.1%, target above 8%. CEO bought at $20.81, now 26% gain — not selling is positive signal. At 9.5x forward, what causes stock to go to $19? Asymmetric risk/reward bullish.

Bear Researcher

ROUND 1: Q2 earnings is a reporting event, not a catalyst — could disappoint. Nuclear TAM math has no source for 5% share assumption. Government shutdown is recurring risk, not one-time — 8% Q1 headwind. Funded backlog only $6.9B (14.6%) of $47.2B. Quarterly B2B 1.0x is breakeven. Net leverage 3.4x with $300-370M/yr interest. GAAP margins 0.69% net, 1.8% ROE. Death cross on chart confirms institutional selling. Recent insider activity is grants/awards, not buys.

ROUND 2: Bull's kill-switch (EPS below $0.50) proves thesis is fragile — 10-18% miss invalidates everything. $40.3B unfunded backlog = 6.3 years revenue with zero cancellation protection. Quarterly B2B 1.0x is most recent data; LTM converging down as strong quarters roll off. Q1 FCF -$142M requires $667-717M in remaining 3 quarters — steep ramp. Stock was at $16.01 in April 2025; can move 5-10% on no news. 9.5x forward assumes $2.35 EPS; at $2.00 it's 13.1x — not cheap for govt-dependent, debt-laded, low-margin industrial.

Risk Assessment

Aggressive

ROUND 1: 9.5x forward P/E at 43% discount is a textbook setup. Integration fears, shutdown noise, GAAP margin confusion are transient. $47.2B backlog is the anchor at 3.3x coverage. LTM B2B 1.1x means gaining work. Catalyst calendar stacked: May 12 earnings, NDAA markup, MDA SHIELD task orders, UK SMR. Stock was $38.11 in Sep 2024 — 31% below peak on better fundamentals. Would go 7-8% of portfolio. Stop at $22, target $34, ~2:1 reward-to-risk.

ROUND 2: Waiting until after May 12 misses the edge — the discount won't last once recovery is confirmed. Good Q2 could gap stock to $29-30. MDA SHIELD even at 5% of ceiling = $750M annual across awardees; Amentum at 20-30% = $150-225M. December 2024 volume spike was lockup expiration, not recurring. Normal volume supports reasonable sizing.

Conservative

ROUND 1: Liquidity risk — 1.5M avg volume on 244M float, 0.6% daily turnover. Dec 2024 saw 30% single-day drop. Event risk concentration around May 12 is binary. Government dependency is vulnerability, not feature — IDIQ ceilings are aspirational, actual spend 5-15%. MDA SHIELD at 5-15% of $151B = $7.5-22.5B total / 10 yrs, not thesis-changing. Debt trajectory not guaranteed — Q1 FCF -$142M. Ba3 is still speculative grade. Recommend max 2% post-May 12. Stop $23.50, target $30.

ROUND 2: The edge is NOT losing money on a binary event. If we buy at $26.23 and Q2 misses, stock gaps to $21-22 (15-20% loss). If we wait and buy at $29 after good report, we give up ~10% upside but avoid 15-20% downside. Math of waiting is superior: risk 10% upside vs avoid 15-20% downside = 1.5-2:1 in favor of waiting. MDA SHIELD at $150-225M annual is barely 1-1.5% of revenue — not transformational.

Neutral

ROUND 1: Both sides valid. Amentum is a catalyst-driven position, not buy-and-hold. Pre-May 12: 1.5-2% position. Post-May 12 if EPS >= $0.50: scale to 3-4%. Post-May 12 if EPS < $0.50: exit immediately. Stop $22.50, target $32. The risk/reward is attractive but only if disciplined about confirmation gate.

ROUND 2: Aggressive and conservative debating timing but agree on direction: undervalued if executes. Graduated approach balances both concerns. Technical picture shows early stabilization (RSI oversold, MACD crossover, Bollinger bounce) supporting modest initial position. But death cross means intermediate trend still down — do not over-commit until trend reverses.

Analyst Reports

$19.32 $23.87 $28.42 $32.98 $37.53 Apr 2025 Oct 2025 Apr 2026 10.6M AMTM · PRICE & VOLUME$25.34 +14.2%

Daily close (warm umber) with under-fill, volume bars in tan. Trailing range capped at 252 trading days.

Market Analysis

Market Report

Amentum Holdings (AMTM) — Technical Market Analysis

As of April 30, 2026

Price Action Overview

AMTM closed at $26.23 on April 30, 2026, with a dramatic late-session recovery from a low of $25.40. The stock has been in a pronounced downtrend from its April 22 high of $28.54, losing ~8.1% in six sessions. Over the full month of April, the stock declined from $27.06 (April 6 open) to $26.23 — a modest 3.1% drop — but the path was volatile with a 20.7% decline over the trailing three months.

Key Technical Indicators

1. 50-Day SMA ($27.94) BEARISH

Price is trading well below the 50-day SMA, which has been declining steadily from $31.01 (March 31) to $27.94 (April 29). The SMA crossed below the 200-day SMA earlier, confirming a death cross pattern.

2. 200-Day SMA ($27.15) CRITICAL LEVEL

The stock just slipped below the 200-day SMA. Price at $26.23 is 3.4% below this key long-term level. The death cross pattern is confirmed.

3. 10-Day EMA ($26.46) NEAR-TERM WEAKNESS

The 10 EMA has declined sharply. Price is marginally below the 10 EMA, suggesting continued short-term selling pressure.

4. MACD (-0.50 / Signal -0.41) EARLY BULLISH CROSSOVER SIGNAL

MACD histogram turned positive on April 27, suggesting a potential bullish crossover. Waning bearish momentum.

5. RSI (33.9) APPROACHING OVERSOLD

RSI is just above the 30 oversold threshold, suggesting the stock could trigger a bounce.

6. Bollinger Bands TESTING LOWER BAND

Stock bounced off the lower Bollinger Band ($25.44) on April 29. Classic mean-reversion signal.

7. ATR (1.02) MODERATE VOLATILITY

ATR has been compressing, indicating decreasing volatility.

8. VWMA ($27.04) VOLUME-WEIGHTED RESISTANCE

VWMA sits above current price, indicating institutional buying at higher levels.

Support and Resistance

IndicatorValueSignal
50-Day SMA$27.94Bearish (price below)
200-Day SMA$27.15Bearish (death cross)
10-Day EMA$26.46Near-term weakness
MACD-0.50Crossover forming
RSI33.9Near oversold
Bollinger PositionLower bandPotential support
ATR1.02Moderate vol
VWMA$27.04Above price (resistance)

Social Sentiment

Social Sentiment Report

Amentum Holdings (AMTM) — Social Media & Company-Specific News Sentiment

As of April 30, 2026

Analyst Coverage Sentiment

The analyst community is broadly positive on AMTM despite the recent price decline:

Key Social/Company Narrative Themes

1. Post-Merger Identity Formation

Amentum is still in its early post-merger phase. The appointment of Joseph DeNardi as new IR head signals active narrative reshaping.

2. Strong Buy at 43% Peer Discount Narrative

Seeking Alpha analysis (April 1, 2026) argued AMTM is a strong buy at a 43% discount to peers.

3. Nuclear Energy Theme — The SMR Play

Amentum's UK SMR engineering role ($406M contract) and Rolls-Royce SMR partnership have generated buzz around AMTM as a nuclear energy/SMR play.

4. Defense & Government Services Consolidation

AMTM discussed as potential consolidator in fragmented government services space.

5. Insider Buying Signal

CEO Steven Demetriou purchased $100,000 at $20.81 (Feb 2025) and Director Barbara Loughran purchased $4,600 at $21.22.

ThemeSentimentImpact
Analyst coverageBullish (Buy/Outperform)High
Nuclear SMR narrativeVery BullishMedium
Insider buying (historical)BullishMedium
Post-merger integrationNeutral/CautiousMedium
Government dependency riskBearishHigh
Price momentum sentimentBearish (recent decline)Medium

News & Macro

News Report

Amentum Holdings (AMTM) — Global News & Macroeconomic Context

As of April 30, 2026

Macroeconomic Environment

U.S. Defense Budget Trajectory

The FY2027 defense budget process (POM cycle) is underway. DoD priorities emphasize missile defense modernization, nuclear deterrence, and space capabilities — all core Amentum markets. NDAA markup for FY2027 occurs May-June.

Nuclear Renaissance Policy

Global nuclear energy policy is expanding: UK SMR program, Dutch nuclear build program, U.S. nuclear modernization all support Amentum's growth.

Geopolitical Tensions

Middle East tensions intensified in late April 2026. AMTM fell with broader market but geopolitical escalation typically supports defense contractors longer-term.

Interest Rate Environment

Moderate rate environment. Moody's upgrade to Ba3 (from Ba1) is a positive credit development for Amentum's significant debt load.

Key News Events

FactorDirectionAMTM Impact
DoD FY2027 budget processPositiveCore revenue support
Nuclear policy expansionVery PositiveSMR/nuclear growth
Middle East escalationMixedShort neg, long pos
Interest rates/creditPositive (upgrade)Debt cost reduction
Industry consolidationPositiveMarket share gains
Government shutdown riskNegativeQ1 FY2026 already impacted

Fundamental Analysis

Fundamentals Report

Amentum Holdings (AMTM) — Fundamental Analysis & Institutional Data Lanes

As of April 30, 2026

Company Overview

Amentum Holdings, Inc. (NYSE: AMTM) is a global advanced engineering and technology solutions provider. ~50,000 employees across 70+ countries. Formed from 2024 combination of legacy Amentum and Jacobs Critical Mission Solutions.

Financial Health

Institutional Data Lane 1: Item 1A Risk Factors (10-K)

Top 7 risks from FY2025 10-K (filed Nov 25, 2025):

  1. Government Contract Dependency & Concentration (~80% revenue from U.S. federal)
  2. Contract Transitions & Competitive Re-compete Risk
  3. Government Shutdown Risk (8% Q1 revenue headwind)
  4. High Debt Load & Leverage (3.4x net leverage)
  5. Integration Risk from Jacobs CMS Merger
  6. Regulatory & Compliance Risk
  7. Goodwill & Intangible Impairment Risk ($7.6B in goodwill+intangibles)

Institutional Data Lane 2: Customer Concentration

Institutional Data Lane 3: Backlog & Book-to-Bill

QuarterBacklog ($B)Funded ($B)B2B (LTM)B2B (Qtr)
Q4 FY202545.2N/A1.1xN/A
Q1 FY202647.26.91.1x1.0x

Backlog grew +4.4% QoQ. Funded = 14.6% of total. $16.3B Q1 net bookings.

Institutional Data Lane 4: Catalyst Calendar

DateEventImpact
May 12, 2026Q2 FY2026 EarningsHigh
May-Jun 2026FY2027 NDAA MarkupHigh
Jun 30, 2026FY2027 DoD POMMedium
H2 2026UK SMR Wylfa MilestonesMedium
H2 2026MDA SHIELD Task OrdersHigh
Key MetricValueAssessment
Revenue (TTM)$14.2BLarge-scale
Adj. EBITDA Margin8.1%Improving
Net Leverage3.4xHigh but deleveraging
Backlog Coverage3.3x revenueFortress-like
B2B (LTM)1.1xDemand > supply
FCF Guidance FY26$525-575MStrong

Risk Factors (Item 1A)

  1. Government Contract Dependency (~80% revenue from U.S. federal)
  2. Contract Transitions & Re-compete Risk
  3. Government Shutdown Risk (8% Q1 headwind)
  4. High Debt Load & Leverage (3.4x net leverage)
  5. Integration Risk from Jacobs CMS Merger
  6. Regulatory & Compliance Risk
  7. Goodwill & Intangible Impairment Risk ($7.6B)

Filing: SEC EDGAR CIK 0002011286, filed Nov 25, 2025

This document is the confidential work product of the Silent Engineering Fund's internal research process and is intended for partners and authorized personnel only. It does not constitute investment advice, an offer to sell, or a solicitation to buy any security. Past performance is not indicative of future results.
Silent Engineering Fund · Internal Research